{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:25:56Z","timestamp":1792758356845,"version":"4.5.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"Importance<\/jats:title>Transitioning from metered-dose inhalers to propellant-free dry-powder inhalers could reduce health care\u2013related greenhouse gas emissions, but the clinical difference in outcomes that may be associated with this switch is uncertain.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the clinical difference in outcomes associated with a July 2021 Veterans Health Administration (VHA) formulary change that replaced budesonide-formoterol metered-dose inhaler with fluticasone-salmeterol dry-powder inhaler for the treatment of chronic obstructive pulmonary disease and asthma.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This within-person, self-controlled case series (SCCS) and matched observational cohort study (cohort study) used data from the US Veterans Affairs health care system from January 2018 through December 2022. Veterans who were prescribed a combination inhaler before and after the formulary change were included in both the SCCS and cohort study. Data were analyzed between April 19, 2024, and April 4, 2025.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Treatment with budesonide-formoterol metered-dose inhaler vs fluticasone-salmeterol dry-powder inhaler.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Rescue medication use (albuterol and prednisone fills), emergency department visits, and hospitalizations (all-cause, respiratory-related, and pneumonia-specific) were assessed.<\/jats:p><\/jats:sec>Results<\/jats:title>Following the VHA formulary change, 260\u202f268 patients switched from budesonide-formoterol metered-dose therapy to fluticasone-salmeterol dry-powder therapy. In the SCCS (median [IQR] age, 71 [62-75] years; 91% male), among patients who switched inhalers and experienced the adverse outcomes of interest, treatment with fluticasone-salmeterol dry-powder inhaler therapy was associated with a 10% decrease in albuterol fills (incidence rate ratio [IRR], 0.90 [95% CI, 0.90-0.91]), a 2% increase in prednisone fills (IRR, 1.02 [95% CI, 1.01-1.03]), a 5% increase in all-cause emergency department visits (IRR, 1.05 [95% CI, 1.04-1.06]), an 8% increase in all-cause hospitalizations (IRR, 1.08 [95% CI, 1.06-1.09]), a 10% increase in respiratory-related hospitalizations (IRR, 1.10 [95% CI, 1.07-1.14]), and a 24% increase in pneumonia-specific hospitalizations (IRR, 1.24 [95% CI, 1.17-1.31]). In the cohort study of 258\u202f557 patients (mean [SD] age, 68.9 [11.3] years; 94% male), those who switched to a fluticasone-salmeterol dry-powder inhaler had no difference in mortality (1.89% vs 1.90%; adjusted absolute difference, \u22120.01 percentage points [95% CI, \u22120.12 to 0.10 percentage points]) but had increases in all-cause hospitalizations (16.14% vs 15.64%; adjusted absolute difference, 0.49 percentage points [95% CI, 0.21-0.78 percentage points]), respiratory-related hospitalizations (3.15% vs 2.74%; adjusted absolute difference, 0.41 percentage points [95% CI, 0.27-0.55 percentage points]), and pneumonia-related hospitalizations (1.15% vs 1.03%; adjusted absolute difference, 0.12 percentage points [95% CI, 0.04-0.21 percentage points]) at 180 days after the switch compared with matched patients who did not switch.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The study found that the VHA formulary transition from budesonide-formoterol metered-dose inhaler to fluticasone-salmeterol dry-powder inhaler was associated with increased health care utilization, suggesting potential harm and the need to reevaluate this policy change.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamainternmed.2025.2299","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:00:35Z","timestamp":1751886035000},"page":"1005","source":"Crossref","is-referenced-by-count":28,"title":["Budesonide-Formoterol Metered-Dose Inhaler vs Fluticasone-Salmeterol Dry-Powder Inhaler"],"prefix":"10.1001","volume":"185","author":[{"given":"Alexander S.","family":"Rabin","sequence":"first","affiliation":[{"name":"Pulmonary Section, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"},{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Seelye","sequence":"additional","affiliation":[{"name":"Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien B.","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"},{"name":"Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cainnear K.","family":"Hogan","sequence":"additional","affiliation":[{"name":"Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor N.","family":"Whittington","sequence":"additional","affiliation":[{"name":"Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cano","sequence":"additional","affiliation":[{"name":"Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelie A.","family":"Miller","sequence":"additional","affiliation":[{"name":"School for Environment and Sustainability, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Kelley","sequence":"additional","affiliation":[{"name":"Veterans Affairs Pharmacy Benefits Management Services, Hines, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallie C.","family":"Prescott","sequence":"additional","affiliation":[{"name":"Pulmonary Section, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"},{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"},{"name":"Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"ioi250037r1","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1001\/jama.2024.15331","article-title":"Greenhouse gas emissions and costs of inhaler devices in the US.","volume":"332","author":"Tirumalasetty","year":"2024","journal-title":"JAMA"},{"issue":"26","key":"ioi250037r2","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1056\/NEJMp2302197","article-title":"Hydrofluorocarbons, climate, and health \u2014 moving the Montreal protocol beyond ozone-layer recovery.","volume":"388","author":"Woodcock","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"ioi250037r3","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1513\/AnnalsATS.202202-131VP","article-title":"Small devices, big problems: addressing the global warming potential of metered-dose inhalers.","volume":"19","author":"Rabin","year":"2022","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"ioi250037r5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/24745332.2023.2254283","article-title":"Canadian Thoracic Society position statement on climate change and choice of inhalers for patients with respiratory disease.","volume":"7","author":"Gupta","year":"2023","journal-title":"Can J Respir Crit Care Sleep Med"},{"issue":"6","key":"ioi250037r7","first-page":"589","article-title":"Consensus statement: aerosols and delivery devices.","volume":"45","author":"Dolovich","year":"2000","journal-title":"Respir Care"},{"issue":"3","key":"ioi250037r8","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jaip.2023.10.027","article-title":"Regulatory and insurance challenges must be overcome in the United States to meet global standards for asthma management.","volume":"12","author":"Arora","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"ioi250037r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49234","article-title":"Implementation of a metered-dose inhaler to dry-powder inhaler national formulary transition.","volume":"7","author":"Rabin","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"ioi250037r11","doi-asserted-by":"publisher","DOI":"10.1080\/15412555.2024.2328708","article-title":"Comparative efficacy of budesonide\/formoterol versus fluticasone\/salmeterol in patients with moderate-to-severe chronic obstructive pulmonary disease: a systematic review and meta-analysis.","volume":"21","author":"Shang","year":"2024","journal-title":"COPD"},{"issue":"106645","key":"ioi250037r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106645","article-title":"Comparing initial LABA-ICS inhalers in COPD: real-world effectiveness and safety.","volume":"189","author":"Suissa","year":"2021","journal-title":"Respir Med"},{"key":"ioi250037r13","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.2147\/COPD.S269637","article-title":"Intraclass difference in pneumonia risk with fluticasone and budesonide in COPD: a systematic review of evidence from direct-comparison studies.","volume":"15","author":"Lodise","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"12","key":"ioi250037r14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004106.pub4","article-title":"Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children.","volume":"2011","author":"Lasserson","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"ioi250037r15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jaip.2014.07.016","article-title":"Comparative effectiveness of budesonide-formoterol combination and fluticasone-salmeterol combination for asthma management: a United States retrospective database analysis.","volume":"2","author":"Tunceli","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1S","key":"ioi250037r17","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.jaip.2021.10.011","article-title":"A practical guide to implementing SMART in asthma management.","volume":"10","author":"Reddel","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ioi250037r18","doi-asserted-by":"publisher","author":"Feldman","journal-title":"BMJ","DOI":"10.1136\/bmj-2024-080409"},{"issue":"1","key":"ioi250037r22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13104-024-06770-3","article-title":"Development and validation of a pulmonary function test data extraction tool for the US department of veterans affairs electronic health record.","volume":"17","author":"Rabin","year":"2024","journal-title":"BMC Res Notes"},{"issue":"2","key":"ioi250037r23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/1077558703060002007","article-title":"VHA enrollees\u2019 health care coverage and use of care.","volume":"60","author":"Shen","year":"2003","journal-title":"Med Care Res Rev"},{"issue":"11","key":"ioi250037r24","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/thoraxjnl-2018-212957","article-title":"Cost saving of switching to equivalent inhalers and its effect on health outcomes.","volume":"74","author":"Bloom","year":"2019","journal-title":"Thorax"},{"key":"ioi250037r25","doi-asserted-by":"publisher","first-page":"i4515","DOI":"10.1136\/bmj.i4515","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs.","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ"},{"issue":"10","key":"ioi250037r26","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/sim.2302","article-title":"Tutorial in biostatistics: the self-controlled case series method.","volume":"25","author":"Whitaker","year":"2006","journal-title":"Stat Med"},{"key":"ioi250037r27","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.2147\/COPD.S431829","article-title":"Inhaler adherence in COPD: a crucial step towards the correct treatment.","volume":"18","author":"Tur\u00e9gano-Yedro","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"ioi250037r28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jaip.2021.11.003","article-title":"The impact of adherence and health literacy on difficult-to-control asthma.","volume":"10","author":"Zaeh","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"ioi250037r29","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1177\/1536867X0900900402","article-title":"Cem: coarsened exact matching in Stata.","volume":"9","author":"Blackwell","year":"2009","journal-title":"Stata J"},{"issue":"21","key":"ioi250037r30","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1001\/jama.2022.21506","article-title":"Adjustment for baseline characteristics in randomized clinical trials.","volume":"328","author":"Holmberg","year":"2022","journal-title":"JAMA"},{"key":"ioi250037r32","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.2147\/COPD.S332151","article-title":"Comparison of risk of pneumonia caused by fluticasone propionate versus budesonide in chronic obstructive pulmonary disease: a nationwide retrospective cohort study.","volume":"16","author":"Choi","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"ioi250037r33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010115.pub2","article-title":"Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.","volume":"2014","author":"Kew","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"ioi250037r34","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41591-022-01714-5","article-title":"Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma.","volume":"28","author":"Kachroo","year":"2022","journal-title":"Nat Med"},{"key":"ioi250037r35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.rmed.2016.09.015","article-title":"Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device.","volume":"120","author":"Dekhuijzen","year":"2016","journal-title":"Respir Med"},{"issue":"3","key":"ioi250037r36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1752-699X.2011.00244.x","article-title":"Fluticasone furoate\/fluticasone propionate - different drugs with different properties.","volume":"5","author":"Biggadike","year":"2011","journal-title":"Clin Respir J"},{"issue":"1","key":"ioi250037r37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.pupt.2008.11.010","article-title":"Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study.","volume":"22","author":"Cote","year":"2009","journal-title":"Pulm Pharmacol Ther"},{"key":"ioi250037r38","author":"L\u00f6tvall","year":"2001","journal-title":"Respir Med"},{"key":"ioi250037r39","doi-asserted-by":"publisher","year":"2020","journal-title":"J Allergy Clin Immunol","DOI":"10.1016\/j.jaci.2020.10.003"},{"issue":"12","key":"ioi250037r40","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1136\/thoraxjnl-2021-218088","article-title":"Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis.","volume":"77","author":"Woodcock","year":"2022","journal-title":"Thorax"},{"key":"ioi250037r41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/COPD.S291030","article-title":"Comparison of dry-powder inhaler and pressurized metered-dose inhaler formulations of extrafine beclomethasone dipropionate\/formoterol fumarate\/glycopyrronium in patients with COPD: the TRI-D randomized controlled trial.","volume":"16","author":"Beeh","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"ioi250037r42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4103\/atm.atm_438_22","article-title":"The impact of unsupervised and unconsented switch of inhalers in patients with controlled asthma \u2014 a targeted literature review.","volume":"18","author":"Albanna","year":"2023","journal-title":"Ann Thorac Med"},{"key":"ioi250037r43","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.2147\/COPD.S79635","article-title":"Switching treatments in COPD: implications for costs and treatment adherence.","volume":"10","author":"Braido","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ioi250037r44","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jpeds.2021.03.008","article-title":"Impact of payor-initiated switching of inhaled corticosteroids on lung function.","volume":"234","author":"Bickel","year":"2021","journal-title":"J Pediatr"},{"issue":"9","key":"ioi250037r45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.32515","article-title":"Changes in US veterans\u2019 access to specialty care during the COVID-19 pandemic.","volume":"5","author":"Griffith","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"11","key":"ioi250037r46","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.4187\/respcare.05445","article-title":"Inhaler training delivered by internet-based home videoconferencing improves technique and quality of life.","volume":"62","author":"Thomas","year":"2017","journal-title":"Respir Care"},{"issue":"1","key":"ioi250037r47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41533-022-00318-3","article-title":"Clinical recommendations for dry powder inhaler use in the management of COPD in primary care.","volume":"32","author":"Leving","year":"2022","journal-title":"NPJ Prim Care Respir Med"},{"issue":"23","key":"ioi250037r48","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMp2115675","article-title":"Decarbonizing the U.S. health sector \u2014 a call to action.","volume":"385","author":"Dzau","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"ioi250037r49","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/aje\/kwae231","article-title":"Grace periods and exposure misclassification in self-controlled case-series studies of drug-drug interactions.","volume":"194","author":"Zhang","year":"2025","journal-title":"Am J Epidemiol"},{"key":"ioi250037r21"},{"key":"ioi250037r31"},{"key":"ioi250037r4","unstructured":"Delivering a \u2018net zero\u2019 National Health Service. NHS England. Accessed November 5, 2024. https:\/\/www.england.nhs.uk\/greenernhs\/publication\/delivering-a-net-zero-national-health-service\/"},{"key":"ioi250037r6","unstructured":"Reducing the environmental impact of asthma treatment. National Asthma Council Australia. Accessed November 15, 2024. https:\/\/www.nationalasthma.org.au\/living-with-asthma\/resources\/health-professionals\/information-paper\/reducing-the-environmental-impact-of-asthma-treatment"},{"key":"ioi250037r9","unstructured":"US Dept of Veterans Affairs. Formulary Advisor. Accessed June 12, 2024. https:\/\/www.va.gov\/formularyadvisor\/class\/RE109"},{"key":"ioi250037r16","unstructured":"2024 GINA Main Report: global strategy for asthma management and prevention. Global Initiative for Asthma. May 7, 2024. Accessed November 23, 2024. https:\/\/ginasthma.org\/2024-report\/"},{"key":"ioi250037r19","unstructured":"Office of procurement, acquisition and logistics (OPAL). US Department of Veterans Affairs. Accessed April 3, 2025. https:\/\/www.va.gov\/opal\/nac\/fss\/pharmprices.asp"},{"key":"ioi250037r20","unstructured":"Pharmacy benefits management services. US Department of Veterans Affairs. Accessed November 18, 2024. https:\/\/www.pbm.va.gov\/nationalformulary.asp"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2836268\/jamainternal_rabin_2025_oi_250037_1753201836.04181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T15:00:56Z","timestamp":1754319656000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2836268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.2299","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}